litlas
Log inCreate account

James R. Seibold

Active 1982–2025

69
Papers
20,371
Citations
64
h-index
68
i10-index

Citations

Citations per year for James R. Seibold1982: 7 citations1984: 1 citations1985: 5 citations1986: 2 citations1987: 2 citations1988: 2 citations1989: 3 citations1990: 7 citations1991: 6 citations1992: 6 citations1993: 5 citations1994: 13 citations1995: 11 citations1996: 19 citations1997: 15 citations1998: 14 citations1999: 28 citations2000: 47 citations2001: 40 citations2002: 39 citations2003: 58 citations2004: 55 citations2005: 53 citations2006: 73 citations2007: 112 citations2008: 92 citations2009: 137 citations2010: 108 citations2011: 104 citations2012: 104 citations2013: 89 citations2014: 115 citations2015: 143 citations2016: 192 citations2017: 168 citations2018: 114 citations2019: 670 citations2020: 581 citations2021: 515 citations2022: 435 citations2023: 261 citations2024: 450 citations2025: 177 citations2026: 5 citations1983: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,270 citing papers, 20.3% of this breakdownUnited Kingdom: 594 citing papers, 9.5% of this breakdownItaly: 584 citing papers, 9.3% of this breakdownFrance: 413 citing papers, 6.6% of this breakdownGermany: 390 citing papers, 6.2% of this breakdownCanada: 290 citing papers, 4.6% of this breakdownSwitzerland: 262 citing papers, 4.2% of this breakdownJapan: 231 citing papers, 3.7% of this breakdownChina: 230 citing papers, 3.7% of this breakdownNetherlands: 210 citing papers, 3.4% of this breakdownAustralia: 164 citing papers, 2.6% of this breakdownSpain: 156 citing papers, 2.5% of this breakdown
0%20.3%Other 23.4%

Institutions

Fields

  • Medicine91.7%
  • Biochemistry, Genetics and Molecular Biology3.1%
  • Immunology and Microbiology1.8%
  • Neuroscience1.3%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Engineering0.4%
  • Other1.2%

Topics

  • Systemic Sclerosis and Related Diseases22.5%
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis11%
  • Inflammatory Myopathies and Dermatomyositis7.4%
  • Pulmonary Hypertension Research and Treatments4.6%
  • Multiple Sclerosis Research Studies3.2%
  • Dermatologic Treatments and Research2.7%
  • Other48.6%

Coauthors

All papers

Open in search
  1. 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

    Authors: F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen, Sindhu R. Johnson, Murray Baron, Alan Tyndall, Marco Matucci‐Cerinic, Raymond P. Naden, Thomas A. Medsger, Patrícia Carreira, Gabriela Riemekasten, Philip J. Clements, Christopher P. Denton, Oliver Distler, Yannick Allanore, Daniel E. Furst, Armando Gabrielli, Maureen D. Mayes, Jacob M. van Laar, James R. Seibold, László Czirják, Virginia Steen, Murat İnanç, Otylia Kowal‐Bielecka, Ulf Müller‐Ladner, Gabriele Valentini, Douglas J. Veale, Madelon C Vonk, Ulrich A. Walker, Lorinda Chung, David H. Collier, Mary Ellen Csuka, Barri J. Fessler, Serena Guiducci, Ariane L. Herrick, Vivien Hsu, Sergio A. Jiménez, Bashar Kahaleh, Peter A. Merkel, S. Sierakowski, Richard M. Silver, Robert W. Simms, John Varga, Janet Pope - Annals of the Rheumatic Diseases 2013 cited by 3,406

  2. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

    Authors: A. J. Tyndall, Bettina Bannert, Madelon Vonk, Paolo Airó, Franco Cozzi, Patrícia Carreira, Dominique Farge Bancel, Y. Allanore, Ulf Müller‐Ladner, O. Distler, Florenzo Iannone, R. Pellerito, Margarita Pileckytė, Irene Miniati, Lidia P Ananieva, Alexandra Balbir‐Gurman, Nemanja Damjanov, Adelheid Mueller, Gabriele Valentini, G. Riemekasten, Mohammed Tikly, Laura K. Hummers, Maria Henriques, Paola Caramaschi, A Scheja, Blaž Rozman, Evelien Ton, Gabór Kumánovics, Bernard Coleiro, Eva Feierl, G. Szucs, Carlos Alberto von Mühlen, Valeria Riccieri, Srđan Novak, Carlo Chizzolini, Anna Kotulska, Christopher P. Denton, Paulo C Coelho, Ina Kötter, İsmail Şimşek, Paloma García de la Peña Lefebvre, É. Hachulla, James R. Seibold, Simona Rednic, Jiří Štork, Jadranka Morović‐Vergles, Ulrich A. Walker - Annals of the Rheumatic Diseases 2010 cited by 1,428

  3. Cyclophosphamide versus Placebo in Scleroderma Lung Disease

    Authors: Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements, Jonathan Goldin, Michael D. Roth, Daniel E. Furst, Edgar Arriola, Richard M. Silver, Charlie Strange, Marcy B. Bolster, James R. Seibold, D. Riley, Vivien Hsu, John Varga, Dean E. Schraufnagel, Arthur C. Theodore, Robert W. Simms, Robert A. Wise, Fredrick M. Wigley, Barbara White, Virginia Steen, Charles A. Read, Maureen D. Mayes, Ed Parsley, Kamal K. Mubarak, M. Kari Connolly, Jeffrey A. Golden, Mitchell A. Olman, Barri J. Fessler, Naomi F. Rothfield, Mark L. Metersky - New England Journal of Medicine 2006 cited by 1,667

  4. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

    Authors: Keith Sullivan, Ellen Goldmuntz, Lynette Keyes-Elstein, Peter A. McSweeney, Ashley Pinckney, Beverly Welch, Maureen D. Mayes, Richard A. Nash, Leslie J. Crofford, Barry Eggleston, Sharon Castina, Linda M. Griffith, Julia Goldstein, Dennis Wallace, Oana Craciunescu, Dinesh Khanna, Rodney J. Folz, Jonathan Goldin, E. William St. Clair, James R. Seibold, Kristine Phillips, Shin Mineishi, Robert W. Simms, Karen K. Ballen, Mark H. Wener, George E. Georges, Shelly Heimfeld, Chitra Hosing, Stephen J. Forman, Suzanne Kafaja, Richard M. Silver, Leroy Griffing, Jan Storek, Sharon LeClercq, Richard Brasington, Mary Ellen Csuka, Christopher Bredeson, Carolyn A. Keever-Taylor, Robyn T. Domsic, M. Bashar Kahaleh, Thomas A. Medsger, Daniel E. Furst - New England Journal of Medicine 2018 cited by 589

  5. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

    Authors: Gerry Coghlan, Christopher P. Denton, Ekkehard Grünig, Diana Bonderman, Oliver Distler, Dinesh Khanna, Ulf Müller‐Ladner, Janet Pope, Madelon C Vonk, Martin Doelberg, Harbajan Chadha‐Boreham, Harald Heinzl, D Rosenberg, Vallerie V. McLaughlin, James R. Seibold - Annals of the Rheumatic Diseases 2013 cited by 825

  6. Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis

    Authors: Dinesh Khanna, Daniel E. Furst, Philip J. Clements, Yannick Allanore, Murray Baron, Lazlo Czirjak, Oliver Distler, Ivan Foeldvari, Masataka Kuwana, Marco Matucci‐Cerinic, Maureen D. Mayes, Thomas A. Medsger, Peter A. Merkel, Janet Pope, James R. Seibold, Virginia Steen, Wendy Stevens, Christopher P. Denton - Journal of Scleroderma and Related Disorders 2017 cited by 521

  7. Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial

    Authors: Eric L. Matteson, Clive Kelly, Jörg H. W. Distler, Anna‐Maria Hoffmann‐Vold, James R. Seibold, Shikha Mittoo, Paul F. Dellaripa, Martin Aringer, Janet Pope, Oliver Distler, Alexandra James, Rozsa Schlenker‐Herceg, Susanne Stowasser, Manuel Quaresma, Kevin R. Flaherty, the INBUILD Trial Investigators - Arthritis & Rheumatology 2022 cited by 114

  8. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

    Authors: Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, M. Tagliaferri, James R. Seibold, Eduard Gorina - The Journal of Rheumatology 2016 cited by 269

  9. Reliability and validity of the university of california, los angeles scleroderma clinical trial consortium gastrointestinal tract instrument

    Authors: Dinesh Khanna, Ron D. Hays, Paul Maranian, James R. Seibold, Ann Impens, Maureen D. Mayes, Philip J. Clements, Terri Getzug, Nihal Fathi, Amber Bechtel, Daniel E. Furst - Arthritis Care & Research 2009 cited by 247

  10. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

    Authors: Marco Matucci‐Cerinic, CP Denton, D.E. Furst, Maureen D. Mayes, Vivien Hsu, Patrick Carpentier, Fredrick M Wigley, C. M. Black, Barri J. Fessler, Peter A. Merkel, Janet Pope, Nadera Sweiss, Mittie K. Doyle, Bernhard Hellmich, Thomas A. Medsger, A. Morganti, Fabrice Kramer, J H Korn, James R. Seibold - Annals of the Rheumatic Diseases 2010 cited by 498

  11. Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192

    Authors: Christopher P. Denton, Peter A. Merkel, Daniel E. Furst, Dinesh Khanna, Paul Emery, Vivien Hsu, Nancy Silliman, James B. Streisand, John Powell, Anita Åkesson, J. B. M. Coppock, F.H.J. van den Hoogen, Ariane L. Herrick, Maureen D. Mayes, Douglas J. Veale, J Haas, Stephen Ledbetter, Joseph H. Korn, Carol M. Black, James R. Seibold - Arthritis & Rheumatism 2006 cited by 451

  12. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

    Authors: Otylia Kowal‐Bielecka, Robert Landewé, Jérôme Avouac, Sylwia Chwieśko, Irene Miniati, László Czirják, Philip J. Clements, Chris Denton, Dominique Farge, Kim Fligelstone, I Földvari, D E Furst, Ulf Müller‐Ladner, James R. Seibold, Richard M. Silver, Kazuhiko Takehara, B Garay Toth, Alan Tyndall, Gabriele Valentini, F.H.J. van den Hoogen, F Wigley, Francesco Zulian, Marco Matucci‐Cerinic - Annals of the Rheumatic Diseases 2009 cited by 617

  13. The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis

    Authors: Dinesh Khanna, Veronica J. Berrocal, Edward H. Giannini, James R. Seibold, Peter A. Merkel, Maureen D. Mayes, Murray Baron, Philip J. Clements, Virginia Steen, Shervin Assassi, Elena Schiopu, Kristine Phillips, Robert W. Simms, Yannick Allanore, Christopher P. Denton, Oliver Distler, Sindhu R. Johnson, Marco Matucci‐Cerinic, Janet Pope, Susanna Proudman, Jeffrey Siegel, Weng Kee Wong, Athol U. Wells, Daniel E. Furst - Arthritis & Rheumatology 2016 cited by 156

  14. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease

    Authors: Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements, Michael D. Roth, Daniel E. Furst, Richard M. Silver, Jonathan Goldin, Edgar Arriola, Charlie Strange, Marcy B. Bolster, James R. Seibold, D. Riley, Vivien Hsu, John Varga, Dean E. Schraufnagel, Arthur C. Theodore, Robert W. Simms, Robert A. Wise, Fred Wigley, Barbara White, Virginia Steen, Charles A. Read, Maureen D. Mayes, Ed Parsley, Kamal K. Mubarak, M. Kari Connolly, Jeffrey A. Golden, Mitchell A. Olman, Barri J. Fessler, Naomi F. Rothfield, Mark L. Metersky, Dinesh Khanna, Ning Li, Gang Li - American Journal of Respiratory and Critical Care Medicine 2007 cited by 464

  15. Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group

    Authors: Dinesh Khanna, Shikha Mittoo, Rohit Aggarwal, Susanna Proudman, Nicola Dalbeth, Eric L. Matteson, Kevin K. Brown, Kevin Flaherty, Athol U. Wells, James R. Seibold, Vibeke Strand - The Journal of Rheumatology 2015 cited by 190

  16. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

    Authors: Janet Pope, Nicholas Bellamy, James R. Seibold, Murray Baron, Michael H. Ellman, Simon Carette, C. Douglas Smith, Ian Chalmers, Paul Hong, David O'Hanlon, Elżbieta Kamińska, Janet Markland, John Sibley, Luís J. Catoggio, Daniel E. Furst - Arthritis & Rheumatism 2001 cited by 429

  17. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

    Authors: James R. Seibold, Toby M. Maher, Kristin B. Highland, Shervin Assassi, Arata Azuma, Laura K. Hummers, Ulrich Costabel, Ute von Wangenheim, Veronika Kohlbrenner, Martina Gahlemann, Margarida Alves, Oliver Distler - Annals of the Rheumatic Diseases 2020 cited by 80

  18. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist

    Authors: J H Korn, Maureen D. Mayes, M Matucci Cerinic, Maurizio Rainisio, Janet Pope, É. Hachulla, E. Rich, Patrick Carpentier, Jerry A. Molitor, James R. Seibold, Vivien Hsu, Loı̈c Guillevin, Soumya Chatterjee, HH Peter, J. S. Coppock, Ariane L. Herrick, Peter A. Merkel, Robert W. Simms, Christopher P. Denton, Daniel E. Furst, Ngan K. Nguyen, M. D. Gaitonde, Carol M. Black, RAPIDS‐1 Study Group - Arthritis & Rheumatism 2004 cited by 726

  19. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.

    Authors: Daniel E. Fürst, Philip J. Clements, Virginia Steen, Thomas A. Medsger, Alfonse T. Masi, William D’Angelo, Peter A. Lachenbruch, Rafael G. Grau, James R. Seibold - 1998 cited by 278

  20. Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study

    Authors: Fredrick M. Wigley, Robert A. Wise, James R. Seibold, Deborah A. McCloskey, Gregory Kujala, Thomas A. Medsger, Virginia D. Steen, John Varga, Sergio Jimenez, Maureen Mayes, Philip J. Clements, Steven R. Weiner, John Porter, Michael Ellman, Christopher Wise, Lee D. Kaufman, John Williams, William Dole - Annals of Internal Medicine 1994 cited by 423

  21. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon

    Authors: Peter A. Merkel, Karen Herlyn, Richard W. Martin, Jennifer J. Anderson, Maureen D. Mayes, Patrice Bell, Joseph H. Korn, Robert W. Simms, Mary Ellen Csuka, Thomas A. Medsger, Naomi F. Rothfield, Michael H. Ellman, David H. Collier, Arthur Weinstein, Daniel E. Furst, Sergio A. Jiménez, Barbara White, James R. Seibold, Fredrick M. Wigley - Arthritis & Rheumatism 2002 cited by 334

  22. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: High-dose versus low-dose penicillamine trial

    Authors: Philip J. Clements, Eric L. Hurwitz, Weng Kee Wong, James R. Seibold, Maureen D. Mayes, Barbara White, Fredrick M. Wigley, Michael H. Weisman, Walter G. Barr, Larry W. Moreland, Thomas A. Medsger, Virginia Steen, Richard W. Martin, David H. Collier, Arthur Weinstein, Edward V. Lally, John Varga, Steven R. Weiner, Brian S. Andrews, Micha Abeles, Daniel E. Fürst - Arthritis & Rheumatism 2000 cited by 287

  23. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double‐blind, placebo‐controlled trial

    Authors: Dinesh Khanna, Philip J. Clements, Daniel E. Fürst, Joseph H. Korn, Michael H. Ellman, Naomi F. Rothfield, Fredrick M. Wigley, Larry W. Moreland, Richard M. Silver, Youn H. Kim, Virginia Steen, Gary S. Firestein, Arthur F. Kavanaugh, Michael Weisman, Maureen D. Mayes, David H. Collier, Mary Ellen Csuka, Robert W. Simms, Peter A. Merkel, Thomas A. Medsger, Martin E. Sanders, Paul Maranian, James R. Seibold - Arthritis & Rheumatism 2009 cited by 155

  24. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis

    Authors: Bradley J. Rabquer, Pei‐Suen Tsou, Yong Hou, Eshwar Thirunavukkarasu, G. Kenneth Haines, Ann Impens, Kristine Phillips, Bashar Kahaleh, James R. Seibold, Alisa E. Koch - Arthritis Research & Therapy 2011 cited by 85